Declaratory Judgment Ruling Will Add Uncertainty To Generic Launches
Executive Summary
Generic companies are likely to face an increased threat of patent infringement lawsuits on the eve of launch following an appeals court ruling on the standards for seeking a declaratory judgment of noninfringement
You may also be interested in...
Generic Exclusivity Forfeiture Provision Hits Snag In Courts; FTC Wants Fix
A key provision of the Medicare Modernization Act's forfeiture provision for ANDA filers' 180-day exclusivity could be moot if courts continue to refuse to hear petitions by generic companies for declaratory judgments
Generic Exclusivity Forfeiture Provision Hits Snag In Courts; FTC Wants Fix
A key provision of the Medicare Modernization Act's forfeiture provision for ANDA filers' 180-day exclusivity could be moot if courts continue to refuse to hear petitions by generic companies for declaratory judgments
Pravachol Exclusivity Ruling Adds Uncertainty For ANDA Filers, Counsel Says
A court decision reinstating Teva's generic exclusivity rights for Pravachol will make it more difficult for ANDA filers to predict when a dismissed declaratory judgment action could trigger 180-day exclusivity, FDA Associate Chief Counsel Elizabeth Dickinson said Oct. 26